Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC411 in Children With Sickle Cell Disease
NCT02973360Phase 2Unknown
- Sponsor
- Micelle BioPharma
- Start
- Mar 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of docosahexaenoic acid in sickle cell disease (SCD) (4 arms), sponsored by Micelle BioPharma. Primary endpoints: Safety and Tolerability at Month 52 and Change from Baseline in Blood Cells Omega-3 Fatty Acids Index at Month 52. Status: unknown.
02
Drugs
docosahexaenoic acid
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02973360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973360.